RU2018125624A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018125624A3 RU2018125624A3 RU2018125624A RU2018125624A RU2018125624A3 RU 2018125624 A3 RU2018125624 A3 RU 2018125624A3 RU 2018125624 A RU2018125624 A RU 2018125624A RU 2018125624 A RU2018125624 A RU 2018125624A RU 2018125624 A3 RU2018125624 A3 RU 2018125624A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015247069 | 2015-12-18 | ||
| JP2015-247069 | 2015-12-18 | ||
| PCT/JP2016/087481 WO2017104779A1 (en) | 2015-12-18 | 2016-12-16 | Anti-c5 antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018125624A RU2018125624A (ru) | 2020-01-20 |
| RU2018125624A3 true RU2018125624A3 (ru) | 2020-03-27 |
| RU2742606C2 RU2742606C2 (ru) | 2021-02-09 |
Family
ID=58186002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018125624A RU2742606C2 (ru) | 2015-12-18 | 2016-12-16 | Антитела к с5 и способы их применения |
Country Status (36)
| Country | Link |
|---|---|
| EP (2) | EP3390442B1 (ru) |
| JP (5) | JP6088703B1 (ru) |
| KR (2) | KR102467124B1 (ru) |
| CN (2) | CN114478760A (ru) |
| AR (1) | AR107077A1 (ru) |
| AU (1) | AU2016372930B2 (ru) |
| BR (1) | BR112018009067A8 (ru) |
| CA (1) | CA3005592C (ru) |
| CL (1) | CL2018001577A1 (ru) |
| CO (1) | CO2018007374A2 (ru) |
| CR (1) | CR20180364A (ru) |
| DK (1) | DK3390442T5 (ru) |
| EA (1) | EA036756B1 (ru) |
| ES (1) | ES2969440T3 (ru) |
| FI (2) | FI3390442T3 (ru) |
| FR (1) | FR24C1044I2 (ru) |
| HR (1) | HRP20231456T1 (ru) |
| HU (2) | HUE065073T2 (ru) |
| IL (1) | IL259256B2 (ru) |
| LT (2) | LT3390442T (ru) |
| MA (1) | MA44081B1 (ru) |
| MX (2) | MX2018007144A (ru) |
| MY (1) | MY186948A (ru) |
| NL (1) | NL301300I2 (ru) |
| PE (2) | PE20181402A1 (ru) |
| PH (1) | PH12018501282A1 (ru) |
| PL (1) | PL3390442T3 (ru) |
| PT (1) | PT3390442T (ru) |
| RS (1) | RS64998B1 (ru) |
| RU (1) | RU2742606C2 (ru) |
| SA (1) | SA518391704B1 (ru) |
| SG (2) | SG10201709415WA (ru) |
| SI (1) | SI3390442T1 (ru) |
| TW (4) | TWI597292B (ru) |
| UA (1) | UA123774C2 (ru) |
| WO (1) | WO2017104779A1 (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN10515A (ru) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
| RU2510400C9 (ru) | 2007-09-26 | 2014-07-20 | Чугаи Сейяку Кабусики Кайся | Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr |
| KR102469853B1 (ko) | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI761912B (zh) | 2010-11-30 | 2022-04-21 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| MA41294A (fr) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation |
| AU2015365167B2 (en) | 2014-12-19 | 2021-07-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
| KR102467124B1 (ko) * | 2015-12-18 | 2022-11-15 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 사용 방법 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| JP7102353B2 (ja) | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｃ５抗体及びそれらの使用 |
| KR101852739B1 (ko) * | 2016-06-17 | 2018-04-30 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 사용 방법 |
| TWI831965B (zh) | 2016-08-05 | 2024-02-11 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
| CN120571008A (zh) | 2017-12-13 | 2025-09-02 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
| CA3111396A1 (en) | 2018-09-06 | 2020-03-12 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5 antibodies and uses thereof |
| US20220204602A1 (en) * | 2019-04-24 | 2022-06-30 | The Trustees Of The University Of Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof |
| KR20210016333A (ko) | 2019-07-31 | 2021-02-15 | 에프. 호프만-라 로슈 아게 | 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생 |
| CR20220040A (es) | 2019-07-31 | 2022-03-02 | Hoffmann La Roche | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab |
| AU2022227150A1 (en) | 2021-02-24 | 2023-08-17 | F. Hoffmann-La Roche Ag | Regeneration and multiple use of depth filters |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| AU3369999A (en) | 1998-04-02 | 1999-10-25 | Genentech Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
| DE60031793T2 (de) | 1999-12-29 | 2007-08-23 | Immunogen Inc., Cambridge | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
| CA2403425C (en) | 2000-04-11 | 2013-08-27 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1354034B8 (en) | 2000-11-30 | 2008-06-18 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| WO2003015819A1 (en) | 2001-08-17 | 2003-02-27 | Tanox, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
| JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| WO2003085107A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT CONTAINING ANTIBODY COMPOSITION |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
| AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2633311T3 (es) | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Variantes de inmunoglobulina y usos de las mismas |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| RU2399381C2 (ru) * | 2003-02-28 | 2010-09-20 | Антидженикс Инк. | Использование лектинов для активации олигомеризации гликопротеидов и антигенных молекул |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
| UA91823C2 (ru) | 2003-11-05 | 2010-09-10 | Гликарт Биотехнолоджи Аг | Гуманизированная анти-cd20 антигенсвязующая молекула ии типа, которая специфически связывается с cd20 человека |
| DK2489364T3 (en) | 2003-11-06 | 2015-03-02 | Seattle Genetics Inc | Monomethylvaline compounds conjugated to antibodies |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| CA2561533C (en) | 2004-04-13 | 2015-06-16 | Yvo Graus | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CN101437501B (zh) * | 2006-03-02 | 2012-09-05 | 阿莱克申药物公司 | 通过抑制补体活性延长同种异体移植物的存活 |
| ES2527695T3 (es) * | 2006-03-08 | 2015-01-28 | Archemix Llc | Aptámeros de unión a complemento y agentes anti-C5 útiles en el tratamiento de trastornos oculares |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2008113834A2 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| KR102469853B1 (ko) * | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| US20090312673A1 (en) * | 2008-06-14 | 2009-12-17 | Vytronus, Inc. | System and method for delivering energy to tissue |
| BRPI0916668B1 (pt) * | 2008-08-05 | 2021-12-28 | Novartis Ag | Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor |
| NZ602219A (en) | 2010-03-01 | 2014-10-31 | Alexion Pharma Inc | Methods and compositions for treating degos’ disease |
| MX2012010481A (es) * | 2010-03-11 | 2012-10-09 | Rinat Neuroscience Corp | Anticuerpos con union de antigenos dependiente del ph. |
| SI2825036T1 (en) * | 2012-03-16 | 2018-08-31 | Regeneron Pharmaceuticals, Inc. | Light chain antibodies with built-in histidine and genetically modified rodents for their formation |
| TWI619729B (zh) * | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| JP6309521B2 (ja) * | 2012-08-13 | 2018-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体 |
| KR101638931B1 (ko) * | 2013-01-31 | 2016-07-12 | 서울대학교산학협력단 | 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법 |
| WO2015023972A1 (en) | 2013-08-16 | 2015-02-19 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| CA3177696A1 (en) * | 2014-02-20 | 2015-08-27 | Allergan, Inc. | Complement component c5 antibodies |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| AU2015365167B2 (en) * | 2014-12-19 | 2021-07-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
| KR102467124B1 (ko) * | 2015-12-18 | 2022-11-15 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 사용 방법 |
-
2016
- 2016-12-16 KR KR1020177029816A patent/KR102467124B1/ko active Active
- 2016-12-16 EA EA201891410A patent/EA036756B1/ru not_active IP Right Cessation
- 2016-12-16 MX MX2018007144A patent/MX2018007144A/es unknown
- 2016-12-16 SG SG10201709415WA patent/SG10201709415WA/en unknown
- 2016-12-16 AU AU2016372930A patent/AU2016372930B2/en active Active
- 2016-12-16 CN CN202210100411.2A patent/CN114478760A/zh active Pending
- 2016-12-16 HU HUE16875755A patent/HUE065073T2/hu unknown
- 2016-12-16 RU RU2018125624A patent/RU2742606C2/ru active
- 2016-12-16 DK DK16875755.7T patent/DK3390442T5/da active
- 2016-12-16 BR BR112018009067A patent/BR112018009067A8/pt active Search and Examination
- 2016-12-16 SI SI201631761T patent/SI3390442T1/sl unknown
- 2016-12-16 IL IL259256A patent/IL259256B2/en unknown
- 2016-12-16 CN CN201680073493.9A patent/CN108401431B/zh active Active
- 2016-12-16 ES ES16875755T patent/ES2969440T3/es active Active
- 2016-12-16 AR ARP160103886A patent/AR107077A1/es unknown
- 2016-12-16 TW TW105141730A patent/TWI597292B/zh active
- 2016-12-16 KR KR1020177003233A patent/KR101789973B1/ko active Active
- 2016-12-16 TW TW110126762A patent/TWI812979B/zh active
- 2016-12-16 TW TW106127444A patent/TWI747936B/zh active
- 2016-12-16 EP EP16875755.7A patent/EP3390442B1/en active Active
- 2016-12-16 JP JP2016244241A patent/JP6088703B1/ja active Active
- 2016-12-16 EP EP23205683.8A patent/EP4342529A3/en active Pending
- 2016-12-16 RS RS20231255A patent/RS64998B1/sr unknown
- 2016-12-16 MY MYPI2018702302A patent/MY186948A/en unknown
- 2016-12-16 TW TW112127316A patent/TW202344514A/zh unknown
- 2016-12-16 MA MA44081A patent/MA44081B1/fr unknown
- 2016-12-16 PE PE2018001137A patent/PE20181402A1/es unknown
- 2016-12-16 LT LTEPPCT/JP2016/087481T patent/LT3390442T/lt unknown
- 2016-12-16 CR CR20180364A patent/CR20180364A/es unknown
- 2016-12-16 PL PL16875755.7T patent/PL3390442T3/pl unknown
- 2016-12-16 WO PCT/JP2016/087481 patent/WO2017104779A1/en not_active Ceased
- 2016-12-16 FI FIEP16875755.7T patent/FI3390442T3/fi active
- 2016-12-16 SG SG11201610782YA patent/SG11201610782YA/en unknown
- 2016-12-16 PT PT168757557T patent/PT3390442T/pt unknown
- 2016-12-16 UA UAA201805269A patent/UA123774C2/uk unknown
- 2016-12-16 HR HRP20231456TT patent/HRP20231456T1/hr unknown
- 2016-12-16 PE PE2022002449A patent/PE20240365A1/es unknown
- 2016-12-16 CA CA3005592A patent/CA3005592C/en active Active
-
2017
- 2017-02-03 JP JP2017018623A patent/JP6879751B2/ja active Active
-
2018
- 2018-05-30 SA SA518391704A patent/SA518391704B1/ar unknown
- 2018-06-12 MX MX2022014885A patent/MX2022014885A/es unknown
- 2018-06-13 CL CL2018001577A patent/CL2018001577A1/es unknown
- 2018-06-14 PH PH12018501282A patent/PH12018501282A1/en unknown
- 2018-07-13 CO CONC2018/0007374A patent/CO2018007374A2/es unknown
-
2021
- 2021-04-30 JP JP2021077055A patent/JP7208299B2/ja active Active
-
2023
- 2023-01-05 JP JP2023000356A patent/JP2023030197A/ja active Pending
-
2024
- 2024-11-22 FI FIC20240040C patent/FIC20240040I1/fi unknown
- 2024-11-22 LT LTPA2024533C patent/LTPA2024533I1/lt unknown
- 2024-11-22 NL NL301300C patent/NL301300I2/nl unknown
- 2024-11-22 FR FR24C1044C patent/FR24C1044I2/fr active Active
- 2024-11-25 HU HUS2400040C patent/HUS2400040I1/hu unknown
-
2025
- 2025-01-27 JP JP2025011102A patent/JP2025063312A/ja active Pending